Lupus and Diabetes: What Is the Connection?

Lupus and diabetes are connected through multiple overlapping pathways, including shared genetic susceptibility, the metabolic side effects of lupus medications, chronic inflammation that promotes insulin resistance, and kidney damage that can compound when both conditions are present. The relationship runs in several directions: having lupus raises the risk of developing diabetes, certain lupus treatments accelerate that risk further, and when both diseases coexist they amplify each other’s damage to the heart, kidneys, and blood vessels. Understanding these connections matters because managing one condition without accounting for the other can leave serious risks unaddressed.

Shared Genetic and Immune Roots

Lupus (systemic lupus erythematosus, or SLE) and type 1 diabetes are both autoimmune diseases, meaning the immune system attacks the body’s own tissues. In lupus, the targets include joints, skin, kidneys, and other organs. In type 1 diabetes, the immune system destroys the insulin-producing cells in the pancreas. Despite these different targets, research has shown that the genetic regions associated with susceptibility to type 1 diabetes overlap considerably with those linked to lupus, multiple sclerosis, and Crohn’s disease, suggesting a shared underlying genetic architecture for autoimmune conditions in general.¹

A Mendelian randomization study using large-scale genetic data found evidence of a direct causal link running from type 1 diabetes to increased lupus risk. The analysis estimated that genetic liability toward type 1 diabetes raised the odds of developing lupus by roughly 25%.² The same study also found that higher vitamin D levels were associated with lower lupus risk, a finding that fits with broader evidence linking vitamin D deficiency to autoimmune flares in both conditions.

Among children and adolescents with lupus, the co-occurrence of other autoimmune conditions is not rare. Data from a large U.S. pediatric lupus registry found that among patients with documented comorbidity information, about 9% had polyautoimmunity, which included type 1 diabetes alongside autoimmune thyroid disease, celiac disease, and autoimmune hepatitis.³ So while lupus and type 1 diabetes are distinct diseases, they cluster together more than chance would predict.

How Lupus Medications Drive Diabetes Risk

The most straightforward connection between lupus and diabetes is pharmaceutical. Corticosteroids like prednisone are a cornerstone of lupus treatment, especially during disease flares and for serious organ involvement like lupus nephritis. These drugs are powerful anti-inflammatories, but they also raise blood sugar by making cells more resistant to insulin and prompting the liver to release more glucose. Taking daily doses at or above the equivalent of 10 mg of prednisolone roughly doubles the risk of developing diabetes.⁴ The risk is not trivial: steroid-induced diabetes in lupus patients receiving treatment for nephritis is associated with both classic metabolic risk factors (like obesity and family history) and lupus-specific factors related to disease severity.⁵

Hydroxychloroquine, one of the most widely prescribed lupus medications, works in the opposite direction. A population-based study found that lupus patients taking hydroxychloroquine at higher cumulative doses had a dramatically lower risk of developing diabetes compared to those not taking it, with risk cut by roughly 74% at cumulative doses of 129 grams or more.⁴ This protective effect was strong enough to partially offset the diabetes risk from concurrent steroid use. Similar findings have been observed in rheumatoid arthritis patients, where hydroxychloroquine use was associated with about a 38% lower risk of developing diabetes.⁶

This creates a practical calculus for lupus patients and their doctors. Staying on hydroxychloroquine consistently, which is already recommended for virtually all lupus patients to reduce flares and organ damage, carries the added benefit of protecting against diabetes. Minimizing steroid doses whenever possible, and tapering to the lowest effective dose after flares, helps keep glucose levels in check. Guidelines for lupus patients on long-term corticosteroids recommend annual diabetes screening for exactly this reason.⁷

Inflammation, Insulin Resistance, and Metabolic Syndrome

Even apart from medication effects, lupus itself promotes metabolic trouble. The chronic, system-wide inflammation that defines active lupus interferes with how cells respond to insulin. Inflammatory molecules circulating in the blood can block insulin signaling pathways, leading to insulin resistance, the hallmark of type 2 diabetes. Lupus patients also tend to have higher rates of metabolic syndrome, a cluster of conditions that includes elevated blood sugar, excess abdominal fat, high blood pressure, and abnormal cholesterol levels.⁸

The relationship between lupus inflammation and insulin resistance creates a feedback loop. Active lupus worsens metabolic health, and metabolic dysfunction in turn fuels cardiovascular damage, which is already accelerated in lupus patients. The inflammation also tends to be persistent rather than episodic; even between visible flares, low-grade immune activation continues working on blood vessel walls and metabolic pathways. This is part of why lupus patients develop atherosclerosis and heart disease at younger ages than would otherwise be expected.

The Cardiovascular Overlap

Heart disease is the leading cause of death in lupus patients who survive the first few years after diagnosis, and diabetes is one of the traditional risk factors that show up more frequently in lupus populations.⁹ SLE drives accelerated atherosclerosis through a combination of chronic inflammation, autoantibody-mediated damage to blood vessels, and the metabolic side effects of treatment.¹⁰

A striking finding from a large study of U.S. Medicaid recipients puts this in perspective. Lupus patients had a 27% higher risk of nonfatal cardiovascular events compared to age- and sex-matched patients who had diabetes but not lupus, and more than twice the risk of the general population. The disparity was most dramatic in younger adults aged 18 to 39, where cardiovascular events are ordinarily rare.¹¹ When lupus and diabetes coexist in the same person, cardiovascular risk compounds: the inflammatory burden of lupus layers on top of the vascular damage diabetes causes independently. This is why aggressive management of blood pressure, cholesterol, and glucose in lupus patients matters so much, even in young people who might not otherwise be considered at risk.

When Both Diseases Hit the Kidneys

Kidney disease is one of the most feared complications of lupus, with lupus nephritis affecting a substantial fraction of patients. Diabetes is also one of the most common causes of kidney disease worldwide. When both conditions affect the same kidneys, the damage can accelerate rapidly, and distinguishing one cause from the other becomes critical for choosing the right treatment. A kidney biopsy is often the only reliable way to tell whether glomerular changes are driven by lupus, diabetes, or both.¹²

Research into biomarkers of kidney damage has found that standard renal and inflammatory proteins can distinguish sick kidneys from healthy ones, but cannot reliably differentiate between diabetic kidney disease and lupus nephritis based on blood or urine tests alone.¹³ This matters clinically because the treatments differ: lupus nephritis requires immunosuppression, while diabetic kidney disease calls for tight glucose and blood pressure control. Treating for one while missing the other can allow preventable damage.

An encouraging development for patients with both conditions is the growing evidence around SGLT2 inhibitors, a class of diabetes medication originally designed to lower blood sugar by causing the kidneys to excrete more glucose. In a cohort of lupus patients, those using SGLT2 inhibitors had about half the risk of developing lupus nephritis, about a 70% lower risk of needing dialysis, and significantly lower risks of heart failure and death from any cause compared to nonusers.¹⁴ A separate population-based study broadly confirmed the kidney-protective and cardiovascular benefits: SGLT2 inhibitor users with lupus and type 2 diabetes had lower risks of acute kidney injury, chronic kidney disease, and end-stage kidney failure, though the reductions in mortality and lupus nephritis specifically did not reach statistical significance in that analysis.¹⁵ The evidence is promising enough that rheumatologists are paying attention, though randomized trials will be needed before SGLT2 inhibitors become a standard recommendation specifically for kidney protection in lupus.

Gestational Diabetes and Lupus Pregnancy

Pregnancy in women with lupus is already considered high-risk, and whether lupus raises the odds of gestational diabetes is a question that comes up frequently. The answer is nuanced. A systematic review and meta-analysis found that lupus pregnancy does not carry a statistically significant increase in gestational diabetes risk overall, but the analysis identified glucocorticoid use and the presence of anti-double-stranded DNA antibodies as factors that were positively associated with higher risk.¹⁶ In other words, it is the active disease and its treatment that drive the risk, not lupus status by itself.

A cohort study tracking pregnancies in women with lupus found that gestational diabetes occurred in about 2.6% of lupus pregnancies compared to 1.4% in matched non-lupus pregnancies. When looking at all deliveries (including repeat pregnancies), women with lupus had roughly twice the risk of developing gestational diabetes.¹⁷ For first pregnancies alone, the risk did not reach statistical significance. The practical takeaway for pregnant women with lupus: glucose monitoring is important throughout pregnancy, especially if you are on steroids or have active disease markers.

Autoantibodies That Cross Boundaries

One of the more intriguing findings in recent research is that lupus patients sometimes carry autoantibodies associated with diabetes even when they do not have diabetes. A study of women with lupus found that roughly 18% carried diabetes-associated antibodies, including those targeting GAD (an enzyme in pancreatic beta cells) and ZnT8 (a zinc transporter involved in insulin secretion). None of the patients who were followed for up to three and a half years after detection actually developed diabetes during that period.¹⁸ The clinical significance of these antibodies in lupus patients remains unclear. They may reflect the generally hyperactive immune state of lupus, where the immune system churns out antibodies against a wider range of self-targets than it normally would, or they could mark a specific subtype of lupus.

In rare cases, lupus and autoimmune diabetes overlap in a condition called latent autoimmune diabetes of adults, or LADA. A reported case described a normal-weight woman who developed diabetes that did not respond to oral medications and required insulin, alongside an active lupus diagnosis. Her clinical picture resembled type 1 diabetes in some ways but presented later than typical, and she lacked some of the classic islet cell antibodies.¹⁹ These overlapping cases highlight that diabetes in a lupus patient is not always steroid-induced or type 2. Clinicians need to consider autoimmune-mediated diabetes, especially when a lean patient develops diabetes that does not behave as expected.

Diet, Lifestyle, and the Gut

For lupus patients trying to reduce their metabolic and cardiovascular risk, lifestyle interventions carry weight. A cross-sectional study of 280 lupus patients found that greater adherence to a Mediterranean-style diet was associated with lower disease activity scores, less accumulated organ damage, lower levels of the inflammatory marker C-reactive protein, and fewer cardiovascular risk factors.²⁰ While cross-sectional data cannot prove that diet caused these benefits, a dietary pattern rich in vegetables, fish, olive oil, and whole grains is already recommended for diabetes prevention and cardiovascular health in general populations. For lupus patients, who face elevated risks in both areas, the overlap in dietary recommendations is convenient.

Emerging research into the gut microbiome adds another dimension. Lupus patients consistently show altered gut bacteria compared to healthy people, with shifts including an increase in certain inflammatory bacterial species, a reduced ratio of Firmicutes to Bacteroidetes, and lower overall microbial diversity. Some bacterial species have been specifically linked to lupus nephritis. Short-chain fatty acids produced by gut bacteria, particularly butyrate, appear to play a role in regulating immune responses and modulating kidney inflammation in lupus.²¹ Similar gut microbial changes have been observed in type 2 diabetes, raising the possibility that shared dysbiosis contributes to both conditions. Research into probiotics and dietary interventions aimed at restoring microbial balance in lupus is still early, but the conceptual overlap with diabetes-related microbiome research makes this an area to watch.

The Mental Health Factor in Managing Both Conditions

Living with one chronic condition is hard enough. Living with lupus and diabetes simultaneously means navigating two sets of medications, appointments, dietary restrictions, and monitoring routines. Depression is common in lupus patients, with one study finding moderate to very severe depression in about 26% of lupus patients studied.²² Depression was significantly associated with worse medication adherence in lupus patients, as were poor prognostic factors for the disease itself. When diabetes care is added on top, with its own medication schedules and glucose monitoring, the burden of self-management becomes a genuine barrier to good outcomes. Addressing mental health is not a soft recommendation for people juggling these conditions; it is a clinical necessity that directly affects whether treatments work.